Investigational drug · Phase 3
MWN109 3
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM).
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
8
Any phase or sponsor naming "MWN109 3"
First trial start
2025
Aug 23, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MWN109 3", any sponsor or status.
Conditions studied
As listed on its trial records.
- Overweight , Obesity
- Type 2 Diabetes Mellitus (T2DM)
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "MWN109 3" as an intervention, largest first.
- Phase 3 Study of MWN109 Injection in Participants With Overweight or ObesityPivotal-lookingNot yet recruiting
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07778693 · 760 participants (planned) · Start Sep 1, 2026 · Primary completion Sep 2027
Drug: MWN109 1; MWN109 2 and 2 more · For: Overweight , Obesity
Sites: Beijing, China
- Phase 2 Study of MWN109 Tablet in Participants With Overweight or ObesityPivotal-lookingCompleted
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07791524 · 255 participants · Start Jan 5, 2026 · Primary completion Jul 9, 2026
Drug: MWN109 1; MWN109 2 and 3 more · For: Overweight , Obesity
Sites: Luoyang, China
- Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes MellitusPivotal-lookingRecruiting
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07801820 · 240 participants (planned) · Start Jun 23, 2026 · Primary completion Mar 2027
Drug: MWN109 1; MWN109 2 and 4 more · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Beijing, China
- A Study to Evaluate Different Administration Conditions and the Food Effect of MWN109 Tablets in Chinese ParticipantsPivotal-lookingCompleted
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07801326 · 162 participants · Start May 24, 2026 · Primary completion Aug 10, 2026
Drug: MWN109 Tablets · For: Type 2 Diabetes Mellitus (T2DM); Overweight , Obesity
Sites: Kunming, China
- Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With OverweightPivotal-lookingActive, not recruiting
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07791537 · 125 participants · Start Dec 26, 2025 · Primary completion Oct 2026
Drug: MWN109 1; MWN109 2 and 2 more · For: Overweight , Obesity
Sites: Luoyang, China
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or ObesityPivotal-lookingCompleted
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07791654 · 120 participants · Start Aug 23, 2025 · Primary completion Mar 21, 2026
Drug: MWN109 1; MWN109 2 and 2 more · For: Overweight , Obesity
Sites: Luoyang, China
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07787624 · 48 participants · Start Dec 18, 2024 · Primary completion Jul 20, 2025
Drug: MWN109; MWN109 and 1 more · For: Healthy Volunteers
Sites: Kunming, China
Shanghai Minwei Biotechnology Co., LtdIndustry
NCT07787728 · 40 participants · Start Jul 14, 2025 · Primary completion Dec 16, 2025
Drug: MWN109 1; MWN109 2 and 3 more · For: Overweight , Obesity
Sites: Kunming, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Overweight , Obesity
- EcnoglutideXW003, VRB-101Phase 38 trials
Hangzhou Sciwind Biosciences Co., Ltd. · Obesity, Weight Management, OSA - Obstructive Sleep Apnea
- MWN109 1Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 2Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- zovaglutideZT002Phase 33 trials
Beijing QL Biopharmaceutical Co.,Ltd · Obesity, Overweight , Obesity, Overweight or Obesity
- matching dosagePhase 22 trials
Hangzhou Sciwind Biosciences Co., Ltd. · Weight Management, Overweight , Obesity, Overweight and/or Obesity
- MWN109 4Phase 22 trials
Shanghai Minwei Biotechnology Co., Ltd · Type 2 Diabetes Mellitus (T2DM), Overweight , Obesity
- ALV-100Phase 21 trial
Alveus Therapeutics, Inc. · Overweight , Obesity, Adults
- SRSD384Phase 21 trial
Sirius Therapeutics Co., Ltd. · Overweight , Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.